

31-06-06 PCT
APR 03 09 37/70 04 JAN 2006
Express Mail No. EV 687 636 491 US

**INFORMATION
DISCLOSURE STATEMENT**



Address to:
Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Attorney Docket	UCLA-005
First Named Inventor	RAJASEKARAN, AYYAPPAN K.
Application Number	10/509,784 ✓
Confirmation No.	7707
Filing Date	August 22, 2005
Group Art Unit	
Examiner Name	
Title:	"USE OF NA, K-ATPASE alpha-AND beta-SUBUNITS IN BLADDER CANCER DETECTION AND DRUG SCREENING"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. UCLA-005 may be charged thereon.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: January 4, 2006

By: *Pamela J. Sherwood*

Pamela J. Sherwood
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/509,784
Filing Date	August 22, 2005
First Named Inventor	RAJASEKARAN, AYYAPPAN K.
Art Unit	
Examiner Name	
Attorney Docket Number	UCLA-005

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/MD/		Blanco et al., Functional characterization of a testes-specific alpha-subunit isoform of the sodium/potassium adenosinetriphosphatase, 1999, 38(41):13661-9	
		Chiampanichayakul, S., Engagement of Na,K-ATPase beta3 subunit by a specific mAb suppresses T and B lymphocyte activation, Int. Immunol. 14 (12), 1407-1414 (2002), Genbank, accession number NM_001679.1	
		Cousin, P., Physical map of 17p13 and the genes adjacent to p53, Genomics 63 (1), 60-68 2000, Genbank, accession number NM_001678.1	
		Lingrel et al., Structure-function studies of the Na,K-ATPase, (1994) Kidney Int Suppl 1994;44:S32-39	
		Ogawa, H., Homology modeling of the cation binding sites of Na ⁺ -K ⁺ -ATPase, Genbank, Proc. Natl. Acad. Sci. U.S.A. 99 (25), 15977-15982 (2002) accession number NM_000701.2	
		Ruiz, A., Characterization and quantification of full-length and truncated Na,K-ATPase alpha 1 and beta 1 RNA transcripts expressed in human retinal pigment epithelium, Gene 155 (2), 179-184 (1995), Genbank, accession number NM_001677.1	
		Shamraj et al., A putative fourth Na ⁺ , K ⁺ -ATPase alpha-subunit gene is expressed in testis, (1994) Proc Natl Acad Sci U S A 91:12952-56	
		Shull et al., Amino-acid sequence of the catalytic subunit of the (Na ⁺ + K ⁺)ATPase deduced from a complementary DNA, (1985), Nature, 316:691-95	
		Vannmolkot, K.R., Novel mutations in the Na ⁺ , K ⁺ -ATPase pump gene ATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions, Ann. Neurol. 54 (3), 360-366 (2003), Genbank, accession number NM_000702.1	
		Woo et al., Characterization of the fourth alpha isoform of the Na,K-ATPase, 1999 May 1;169(1):39-44	

Examiner Signature	/Minh Tam Davis/ (05/24/2007)	Date Considered	
--------------------	-------------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant is to place a check mark here if English language Translation is attached.
²This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.